Assessing Tolerability in Medullary Thyroid Cancer Treatment
Author Information
Author(s): Regnault Antoine, Bunod Laurine, Loubert Angely, Brose Marcia S., Hess Lisa M., Maeda Patricia, Lin Yan, Speck Rebecca M., Gilligan Adrienne M.
Primary Institution: Modus Outcomes, a THREAD Company, Lyon, France
Hypothesis
Can the Functional Assessment of Cancer Therapy item GP5 effectively measure tolerability in patients with advanced medullary thyroid cancer?
Conclusion
The GP5 is a reliable measure for assessing treatment tolerability in patients with advanced medullary thyroid cancer.
Supporting Evidence
- The GP5 showed good reliability with ICCs between 0.80 and 0.85.
- Significant associations were found between GP5 ratings and PRO-CTCAE scores.
- Patients with higher GP5 ratings reported worse physical functioning.
- 44.5% of patients experienced high side-effect burden at least once during the study.
- GP5 ratings were able to detect changes in patient-reported adverse events over time.
Takeaway
This study shows that a simple question about side effects can help doctors understand how well patients are tolerating their cancer treatment.
Methodology
Blinded, pooled interim data from the safety population of the LIBRETTO-531 trial were analyzed for reliability and validity of GP5 ratings.
Potential Biases
Potential bias due to the structured nature of clinical trial settings affecting treatment adherence.
Limitations
The study did not explore cultural variations in GP5 performance and had a lower completion rate at baseline.
Participant Demographics
Average age was 54.2 years, with 62.8% male and 69.4% White.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website